Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1756-1769
Closed Access | Times Cited: 125

Showing 26-50 of 125 citing articles:

Immunotherapy for early-stage non-small cell lung cancer: A practical guide of current controversies
William J. Phillips, Ashley Jackson, Biniam Kidane, et al.
Clinical Lung Cancer (2025)
Open Access
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Jordi Remón, Martina Bortolot, Paolo Bironzo, et al.
Journal of Clinical Oncology (2025)
Closed Access
Bestätigung für perioperative Immuntherapie beim resektablen Lungenkrebs

Pneumologie (2025) Vol. 79, Iss. 01, pp. 13-14
Closed Access
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Qiong Zhang, Jia Duan, Yuanmei Zhang, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
Suzanne L. Topalian, Drew M. Pardoll
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010833-e010833
Open Access
Comparison of PD-L1 Expression Between Preoperative Biopsy Specimens and Surgical Specimens in Non-Small Cell Lung Cancer
Tadashi Sakaguchi, Akemi Iketani, Kentaro Ito, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 398-398
Open Access
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Liang Zeng, Huan Yan, Wenjuan Jiang, et al.
Med (2025), pp. 100574-100574
Closed Access
Navigating Chemotherapy and Immunotherapy in Early-Stage Lung Cancer. A critical review and statements from INTERACTION group.
Chiara Catania, Claudia Proto, Chiara Bennati, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104633-104633
Closed Access
A stage IIIA lung adenocarcinoma case achieving pathological response with only one cycle of preoperative nivolumab combination chemotherapy
Shuhei Baba, Fumihiko Kinoshita, Yoshihiro Yamamoto, et al.
General Thoracic and Cardiovascular Surgery Cases (2025) Vol. 4, Iss. 1
Open Access
Stage IIIA Non‐Small Cell Lung Cancer Treatment and Outcomes: A Single Institution Retrospective Analysis
Richard Duan, Michelle Kwan, Avram Kordon, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 3
Open Access
Perioperatives Nivolumab beim nicht kleinzelligen Lungenkarzinom

TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 01, pp. 17-18
Closed Access
Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
Wenzhao Li, Wisam Najdawi, Omar Badla, et al.
Seminars in Ophthalmology (2025), pp. 1-11
Closed Access
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab
Francesco Cortiula, Talia Shentzer Kutiel, Melinda Laine Hsu, et al.
European Journal of Cancer (2025) Vol. 219, pp. 115302-115302
Closed Access
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 110-110
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Current efficacy of immune checkpoint inhibitors in microsatellite unstable colorectal cancer and potential biomarkers
Mariam Rojas, Clara Ugueto Rodrigo, Reinaldo Moreno, et al.
(2025) Vol. 4
Open Access
Lung Cancer Therapy: The Role of Personalized Medicine
Raquel Ramos, Conceição Souto Moura, Mariana Fernandes Costa, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 725-725
Open Access
Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
Yan Hu, Siying Ren, Juan Feng, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 2, pp. 467-479
Open Access
Translating premalignant biology to accelerate non-small-cell lung cancer interception
Sarah A. Mazzilli, Zahraa Rahal, Maral J. Rouhani, et al.
Nature reviews. Cancer (2025)
Closed Access
Neoadjuvant chemotherapy and low dose immunotherapy in resectable non-small cell lung cancer – A multi-center retrospective cohort analysis
Minit Shah, Vanita Noronha, Srinivasan Kulandaivel, et al.
Clinical Oncology (2025) Vol. 41, pp. 103795-103795
Closed Access
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review
Xiaolin Zhao, Xiaoyu Wang, Surui Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer
Stephanie P.L. Saw, Angela Takano, Siqin Zhou, et al.
Lung Cancer (2025) Vol. 202, pp. 108463-108463
Open Access
Overcoming common emerging barriers to effective neoadjuvant immunotherapies
Sophia Sokol, Marijo Bilušić
Expert Review of Anticancer Therapy (2025), pp. 1-11
Closed Access

Scroll to top